glp-1 roche Ad hoc announcement pursuant to Art. 53 LR] announces positive Phase I results of its oral receptor agonist CT-996 for the treatment of people with obesity โก๏ธ ๐ฅ๐ผ๐ฐ๐ต๐ฒ ๐ท๐๐๐ ๐ฝ๐ผ๐๐๐ฒ๐ฑ ๐ฃ๐ต๐ฎ๐๐ฒ
Pay in 4 interest-free payments of $7.34 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours ยท Estimated delivery Aug 14 - Aug 19
![glp-1 roche Ad hoc announcement pursuant to Art. 53 LR] announces positive Phase I results of its oral receptor agonist CT-996 for the treatment of people with obesity](https://www.reuters.com/resizer/v2/F33QVZHAVJKINCYYAWNRZGPP2I.jpg?auth=2bf5c4f15a6a09c7e4a68854c7ccf2ea81d0ea0834b9192fb9d93fb1cd369b7a)
![glp-1 roche Ad hoc announcement pursuant to Art. 53 LR] announces positive Phase I results of its oral receptor agonist CT-996 for the treatment of people with obesity](https://qtxasset.com/cdn-cgi/image/w=384,h=216,f=auto,fit=crop,g=0.5x0.5/https://qtxasset.com/quartz/qcloud5/media/image/Structure%20support.jpg?VersionId=IqhUtEq847RmKGNDTcDf7PW7BmOaxUZU)
![glp-1 roche Ad hoc announcement pursuant to Art. 53 LR] announces positive Phase I results of its oral receptor agonist CT-996 for the treatment of people with obesity](https://rejuven8peptides.com/wp-content/uploads/2026/02/rejuven8-peptides-glp1-5mg.png)
![glp-1 roche Ad hoc announcement pursuant to Art. 53 LR] announces positive Phase I results of its oral receptor agonist CT-996 for the treatment of people with obesity](https://www.swissinfo.ch/content/wp-content/uploads/sites/13/2026/04/676660337_highres.jpg?ver=87581e01)




















